FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering
FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering
Source: FDA Drug Safety Podcasts - Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts